



# Balfour Capital Group Intuitive Surgical, Inc.

Intuitive Surgical is a global leader in robotic-assisted, minimally invasive surgery. The company develops, manufactures, and markets the da Vinci Surgical System, which enables surgeons to perform complex procedures with enhanced precision and control. Additionally, Intuitive offers the Ion endoluminal system for minimally invasive lung biopsies. Over the past three decades, more than 15 million procedures have been performed using its systems, with over 76,000 surgeons trained worldwide.

## 1. Top 5 Competitors

Intuitive Surgical operates in a competitive landscape with several key players:

- Medtronic
- Stryker Corporation
- Johnson & Johnson
- Boston Scientific Corporation
- PROCEPT BioRobotics

These companies offer various medical devices and surgical systems that compete with Intuitive's offerings.

## 2. Largest Institutional Shareholders

As of the latest filings, the largest institutional shareholders of Intuitive Surgical include:

- Vanguard Group Inc. – 32.21 million shares (8.99% ownership)
- Fidelity Management & Research Co. LLC – 10.82 million shares (3.03%)
- JPMorgan Investment Management, Inc. – 10.23 million shares (2.87%)
- Geode Capital Management LLC – 7.76 million shares (2.18%)
- BlackRock Life Ltd. – 7.66 million shares (2.15%)



# Balfour Capital Group Intuitive Surgical, Inc.

## 3. Management Team

The executive leadership of Intuitive Surgical comprises:

- Gary S. Guthart, PhD – Chief Executive Officer and Director
- David J. Rosa – President and Director
- Jamie E. Samath – Executive Vice President, Chief Financial Officer, and Enterprise Technology Leader
- Myriam J. Curet, MD, FACS – Executive Vice President and Chief Medical Officer
- Mark P. Brosius – Senior Vice President and Chief Manufacturing and Supply Chain Officer

## 4. Revenue

Intuitive Surgical's financial performance has shown consistent growth:

- Q1 2025 Revenue: \$2.25 billion, a 19% increase year-over-year.
- Full-Year 2024 Revenue: \$8.35 billion, up 17.24% from 2023.
- Trailing Twelve Months (TTM) Revenue as of March 31, 2025: \$8.71 billion, reflecting a 19.08% year-over-year increase.

## 5. Institutions with Buy Recommendations:

Analyst sentiment towards Intuitive Surgical is predominantly positive:

- Nasdaq reports that out of 28 analyst recommendations, 19 are Strong Buy and 2 are Buy, accounting for approximately 75% positive ratings.
- TipRanks indicates a consensus rating of Strong Buy, based on 15 Buy ratings and 3 Hold ratings.

## 6. Analyst Sentiment Summary

Analysts maintain a favorable outlook on Intuitive Surgical:

- Average Price Target: \$575.83.
- Consensus Rating: Buy, with 38% Strong Buy, 33% Buy, 25% Hold, and 3% each for Sell and Strong Sell.



# Balfour Capital Group Intuitive Surgical, Inc.

## 7. Insider Buying and Selling (Last 24 Months)

Insider trading activity over the past two years indicates:

- Shares Sold: 536,003 shares, totaling approximately \$213 million.
- Recent Activity: In the past 6 months, there have been 80 insider sales and no purchases.

